Simple Summary Diffuse large B-cell lymphoma (DLBCL) is the most common high-grade
non-Hodgkin lymphoma. The current treatment combining the anti-CD20 monoclonal …

In relapsed/refractory Hodgkin lymphoma (R/R HL), immunotherapies such as the anti-
programmed death-1 inhibitor pembrolizumab have demonstrated efficacy as monotherapy …

The outcome of patients with relapsed/refractory classical Hodgkin lymphoma (rr-cHL) has
improved considerably in recent years owing to the approval of highly active novel agents …

CAR T-cell therapy is well tolerated and effective in patients with Hodgkin lymphoma (HL)
and anaplastic large cell lymphoma (ALCL). However, even second-generation anti-CD30 …

Simple Summary The evaluation of breast cancer immune microenvironment has been
increasingly used in clinical practice, either by counting tumor infiltrating lymphocytes or …

Non-Hodgkin lymphoma's (NHL) incidence is rising over time, and B cell lymphomas
comprise the majority of lymphomas. The phosphoinositide 3-kinase (PI3K)/v-akt murine …

Purpose Treatment strategies of lymphoid malignancies have been revolutionized by
immunotherapy. Because of the inherent property of Hodgkin lymphoma and some subtypes …

Cancer complicates~ 1 in 1000 pregnancies, which translates into~ 4000 cases annually in
the United States. 1 Lymphoma is the fourth most common malignancy and the most …

The ligation of programmed cell death 1 (PD-1) with programmed cell death ligand PD-L
activates the immune checkpoint leading to T-cell dysfunction, exhaustion, and tolerance …

Autophagy is an evolutionary conserved process that recycles cellular materials in times of
nutrient restriction to maintain viability. In cancer therapeutics, the role of autophagy in …